The select committee of the West African nation's National Assembly submitted its report on December 20 saying the Gambian regulator had relied on a fitness certificate provided by Maiden Pharmaceuticals but the cough syrup maker flouted good manufacturing practices.
The findings of a laboratory in Geneva contradict the findings of India's drug regulator, which gave a clean chit to Maiden Pharmaceuticals in the investigation into the deaths of 69 children in the Gambia.
"It is clear that perhaps premature deduction was drawn on September 29th itself regarding the cause of death. Every subsequent alert or publication from the WHO only seems to be a reaffirmation of.
The central government has said that the four cough syrups produced and exported by Maiden Pharmaceuticals, which are suspected of being responsible for the deaths of 66 children in Gambia, were of standard quality.
The intra-nasal vaccine for COVID received approval under restricted Use in emergency situations for ages 18 and above for primary two dose schedule, homologous booster doses, Union minister Dr Jitendra Singh said.